Paul Scotti (@pscotti)
Activity by Paul Scotti
JACKSONVILLE, Fla. — Patients with liver cancer can be cured with a liver transplant. But because of the shortage of donated organs, these patients often die waiting for a liver. That’s because most transplant centers predominantly use livers from donors who die from brain death.
But in the largest study of its kind, transplant physicians at Mayo Clinic in Florida have found that liver cancer patients have the same beneficial outcomes using organs donated by patients who died of cardiac death. The study was recently published online in the American Journal of Transplantation.
MEDIA CONTACT: Paul Scotti, Mayo Clinic Public Affairs, 904-953-0199, email@example.com
JACKSONVILLE, Fla. — A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is also linked to improved prognosis in patients treated with chemotherapy for HER2-positive breast cancer. But that marker — the quantity of tumor-infiltrating lymphocytes (S-TILs) in a biopsy — appears irrelevant when trastuzumab is used.
JACKSONVILLE, Fla., Nov. 9, 2014 — All patients with hepatitis C who receive a liver transplant will eventually infect their new livers. These transplanted organs then require anti-viral treatment before they become severely damaged. But traditional post-transplant hepatitis C therapy can take up to a year, is potentially toxic and can lead to organ rejection.
Now, at the American Association for the Study of Liver Diseases (The Liver Meeting® 2014) in Boston, researchers at Mayo Clinic report that use of two new oral medications post-transplant is safe and beneficial, and requires only 12 weeks of treatment.
“This is the first study to examine the use of these two new drugs — simeprevir and sofosbuvir — in liver transplant recipients, and, based on this large study, we find it to be a better option than current treatment,” says the study’s lead researcher, Surakit Pungpapong, M.D., a transplant hepatologist and an associate professor of medicine at Mayo Clinic in Florida.
Journalists: Soundbites with Dr. Pungpapong are available in the downloads.
Years After Treatment for HER2-Positive Early Stage Breast Cancer Trastuzumab Shows Life-Altering Benefit
JACKSONVILLE, Fla. — After following breast cancer patients for an average of eight-plus years, researchers say that adding trastuzumab (Herceptin) to chemotherapy significantly improved the overall and disease-free survival of women with early stage HER2-positive breast cancer.
They found that the use of trastuzumab produced a 37 percent improvement in survival and a 40 percent reduction in risk of cancer occurrence, compared to patients treated with chemotherapy alone.
These findings, published in the Journal of Clinical Oncology, demonstrate how important trastuzumab has been to the treatment of this form of breast cancer, says the study’s lead author, Edith A. Perez, M.D., deputy director at large, Mayo Clinic Cancer Center and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida. [...]
JACKSONVILLE, Flórida 30 de setembro de 2014 — Análises em mais de 8 mil mulheres, que participaram do maior estudo mundial de dois medicamentos para o câncer de mama HER2-positivo, reforçam outras descobertas de estudos clínicos mostrando que o trastuzumabe (Herceptin) deve permanecer como o padrão de tratamento desse tipo de câncer, diz uma pesquisadora da Clínica Mayo. [...]
JACKSONVILLE, Florida, 30 de septiembre 2014 — Investigaciones en más de 8.000 mujeres, que participaron en el estudio más grande del mundo de dos tratamientos para el cáncer de mama HER2-positivo, refuerzan otros hallazgos de este ensayo clínico que demuestran que el fármaco trastuzumab (Herceptin) debiera seguir siendo el tratamiento estándar en este tipo de cáncer, expresa una investigadora de la Clínica Mayo. [...]
JACKSONVILLE, Fla., Sept. 29, 2014 — Analysis of more than 8,000 women who participated in the world’s largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a Mayo Clinic researcher.
JACKSONVILLE, Fla., Sept. 12, 2014 — The liver transplant team at Mayo Clinic in Florida has found, based on 12 years of experience, that more than half of patients receiving a new liver can be “fast-tracked” to return to a surgical ward room following their transplant, bypassing a one- or two-day stay in the Intensive Care Unit (ICU).
In the September issue of the American Journal of Transplantation, the physicians and researchers have turned their knowledge of who can be safely fast-tracked into a scoring system that other transplant centers can also use — thus sparing patients potentially overly aggressive treatment and saving substantial health care dollars.